<?xml version="1.0" encoding="UTF-8"?>
<p id="par0160">A novel approach involves binding to the CoV itself through a soluble version of the ACE2 receptor, fused to an immunoglobulin Fc domain (ACE2-Fc) that binds to the S protein of SARS-CoV-2 and neutralizes the virus (
 <xref rid="fig0005" ref-type="fig">Fig. 1</xref>). This methodology would allow for maximal breath, maximally engage the immune system to build lasting immunity, and decrease ACE2 levels in the lungs during infection, thus impacting acute respiratory distress pathophysiology 
 <xref rid="bib0375" ref-type="bibr">[75]</xref>. Testing for the efficacy and safety of this novel therapeutic strategy is necessary, prior to clinical implementation.
</p>
